Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone.
If approved, the system would be the first of its kind, according to the Billerica, Mass.-based company.
All Samsung mobile devices are built with the Samsung Knox mobile security platform, according to Insulet, which will complement the security features provided by Insulet’s FDA-cleared Omnipod Dash mobile app.
